Positive News SentimentPositive NewsNASDAQ:URGN UroGen Pharma (URGN) Stock Price, News & Analysis $16.35 -0.01 (-0.06%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$15.99▼$16.7850-Day Range$12.72▼$19.2052-Week Range$8.77▼$24.13Volume314,828 shsAverage Volume470,223 shsMarket Capitalization$383.41 millionP/E RatioN/ADividend YieldN/APrice Target$51.17 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get UroGen Pharma alerts: Email Address UroGen Pharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside212.9% Upside$51.17 Price TargetShort InterestHealthy25.03% of Shares Sold ShortDividend StrengthN/ASustainability-1.33Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$67,401 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.52) to ($2.52) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.54 out of 5 starsMedical Sector99th out of 936 stocksPharmaceutical Preparations Industry36th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingUroGen Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageUroGen Pharma has only been the subject of 3 research reports in the past 90 days.Read more about UroGen Pharma's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted25.03% of the outstanding shares of UroGen Pharma have been sold short.Short Interest Ratio / Days to CoverUroGen Pharma has a short interest ratio ("days to cover") of 9.5.Change versus previous monthShort interest in UroGen Pharma has recently decreased by 7.41%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldUroGen Pharma does not currently pay a dividend.Dividend GrowthUroGen Pharma does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreUroGen Pharma has received a 70.26% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Other cancer medication", "Clinical research services for physical health", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for UroGen Pharma is -1.33. Previous Next 3.8 News and Social Media Coverage News SentimentUroGen Pharma has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for UroGen Pharma this week, compared to 2 articles on an average week.Search Interest5 people have searched for URGN on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.MarketBeat Follows5 people have added UroGen Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, UroGen Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $67,401.00 in company stock.Percentage Held by InsidersOnly 5.10% of the stock of UroGen Pharma is held by insiders.Percentage Held by Institutions91.29% of the stock of UroGen Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about UroGen Pharma's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for UroGen Pharma are expected to grow in the coming year, from ($3.52) to ($2.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of UroGen Pharma is -4.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of UroGen Pharma is -4.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about UroGen Pharma's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIHow a $0.25 cent option contract makes my top traders feelIf you don’t know me, I’ve been in the markets for over 40 years… but recently, I’ve discovered a breakthrough that might be my favorite strategy of ALL time! While I kept the finer details of these $0.25 Cent Trades under wraps until recently…Click now to see for yourself what $0.25 Cent Trades is all about About UroGen Pharma Stock (NASDAQ:URGN)UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.Read More URGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart URGN Stock News HeadlinesJune 17, 2024 | businesswire.comUroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded WarrantsJune 17, 2024 | globenewswire.comUroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded WarrantsJuly 26, 2024 | American Hartford Gold Group (Ad)Prepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.June 13, 2024 | investors.comUroGen Catapults On 'Unprecedented' Results For Gel-Based Cancer DrugJune 13, 2024 | businesswire.comUber Advertising Announces Exclusive Partnership with T-Mobile Advertising SolutionsJune 13, 2024 | businesswire.comAscellaHealth Chairman and President Bill Oldham Named 2024 Philadelphia Titan 100June 13, 2024 | businesswire.comUroGen Announces Unprecedented 82.3% Duration of Response at 12 Months in the ENVISION Trial Investigating UGN-102 as Potentially the First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBCJune 7, 2024 | businesswire.comUroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 26, 2024 | American Hartford Gold Group (Ad)Prepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.June 6, 2024 | businesswire.comUroGen Pharma to Host UGN-102 Virtual Data Event on June 13, 2024June 5, 2024 | businesswire.comUroGen Pharma to Present at the 45th Annual Goldman Sachs Global Healthcare ConferenceJune 3, 2024 | businesswire.comUroGen Pharma Appoints David Lin as New Chief Commercial OfficerMay 22, 2024 | businesswire.comUroGen Pharma to Present at the TD Cowen 5th Annual Oncology Innovation SummitMay 14, 2024 | markets.businessinsider.comUroGen Pharma Holds Steady Amidst Financial Underperformance and Anticipated Study ResultsMay 14, 2024 | markets.businessinsider.comBuy Rating Affirmed for Urogen Pharma as UGN-102 Progresses Towards FDA Approval and Market SuccessMay 14, 2024 | msn.comUroGen Pharma Ltd. (NASDAQ:URGN) Q1 2024 Earnings Call TranscriptMay 14, 2024 | finance.yahoo.comUroGen Pharma Ltd (URGN) Q1 2024 Earnings Call Transcript Highlights: Key Financials and ...May 14, 2024 | finance.yahoo.comUroGen Pharma First Quarter 2024 Earnings: Misses ExpectationsSee More Headlines Receive URGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for UroGen Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:URGN CUSIPN/A CIK1668243 Webwww.urogen.com Phone(646) 768-9780FaxN/AEmployees200Year FoundedN/APrice Target and Rating Average Stock Price Target$51.17 High Stock Price Target$60.00 Low Stock Price Target$40.00 Potential Upside/Downside+212.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($3.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-102,240,000.00 Net Margins-123.74% Pretax Margin-119.05% Return on EquityN/A Return on Assets-62.48% Debt Debt-to-Equity RatioN/A Current Ratio7.47 Quick Ratio7.20 Sales & Book Value Annual Sales$82.71 million Price / Sales4.64 Cash FlowN/A Price / Cash FlowN/A Book Value($2.78) per share Price / Book-5.88Miscellaneous Outstanding Shares23,450,000Free Float22,258,000Market Cap$383.41 million OptionableOptionable Beta1.12 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMs. Elizabeth A. Barrett (Age 62)President, CEO & Director Comp: $1.34MMr. Jason Drew Smith (Age 52)General Counsel, Chief Compliance Officer & Corporate Secretary Comp: $864.19kDr. Mark P. Schoenberg M.D. (Age 66)Chief Medical Officer Comp: $639.83kMr. Dong Kim (Age 46)Chief Financial Officer Comp: $546.68kVincent I. PerroneSenior Director of Investor RelationsMr. Bryon WornsonExecutive Vice President of Talent, Advocacy & CommunicationsDr. Marina KonortyExecutive Vice President of Research & Development and Technical OperationsMr. Jeffrey Bova M.B.A.Chief Commercial OfficerMr. James Ottinger R.ph.Executive Vice President of Regulatory Affairs & QualityDr. Polly A. Murphy D.V.M. (Age 59)M.B.A., Ph.D., Chief Business Officer More ExecutivesKey CompetitorsAkebia TherapeuticsNASDAQ:AKBASpectrum PharmaceuticalsNASDAQ:SPPIPuma BiotechnologyNASDAQ:PBYIRAPT TherapeuticsNASDAQ:RAPTMarinus PharmaceuticalsNASDAQ:MRNSView All CompetitorsInsiders & InstitutionsARK Investment Management LLCBought 5,452 shares on 7/26/2024Ownership: 0.647%Bank of New York Mellon CorpBought 28,400 shares on 7/26/2024Ownership: 0.412%Harel Insurance Investments & Financial Services Ltd.Sold 209,922 shares on 7/22/2024Ownership: 1.977%Oak Ridge Investments LLCBought 18,725 shares on 7/17/2024Ownership: 0.341%Shikiar Asset Management Inc.Sold 22,500 shares on 7/16/2024Ownership: 0.046%View All Insider TransactionsView All Institutional Transactions URGN Stock Analysis - Frequently Asked Questions How have URGN shares performed this year? UroGen Pharma's stock was trading at $15.00 at the beginning of the year. Since then, URGN stock has increased by 9.0% and is now trading at $16.35. View the best growth stocks for 2024 here. How were UroGen Pharma's earnings last quarter? UroGen Pharma Ltd. (NASDAQ:URGN) issued its quarterly earnings results on Monday, May, 13th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.93) by $0.04. The business had revenue of $18.78 million for the quarter, compared to analyst estimates of $20.73 million. When did UroGen Pharma IPO? UroGen Pharma (URGN) raised $46 million in an IPO on Thursday, May 4th 2017. The company issued 3,500,000 shares at a price of $12.00-$14.00 per share. Jefferies and Cowen and Company acted as the underwriters for the IPO and Raymond James and Oppenheimer were co-managers. Who are UroGen Pharma's major shareholders? UroGen Pharma's top institutional shareholders include Harel Insurance Investments & Financial Services Ltd. (1.98%), ARK Investment Management LLC (0.65%), Bank of New York Mellon Corp (0.41%) and Oak Ridge Investments LLC (0.34%). Insiders that own company stock include Mark Schoenberg, Jason Drew Smith, Elizabeth A Barrett and Molly Henderson. View institutional ownership trends. How do I buy shares of UroGen Pharma? Shares of URGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of UroGen Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that UroGen Pharma investors own include Sorrento Therapeutics (SRNE), Micron Technology (MU), OPKO Health (OPK), TG Therapeutics (TGTX), VBI Vaccines (VBIV), Exelixis (EXEL) and (KITE) (KITE). This page (NASDAQ:URGN) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredWhy is NVDA stumbling?July is historically the best month of the year for U.S. stocks. So why are everyone’s favorite tech stocks...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding UroGen Pharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share UroGen Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
